Skip to main content

Advertisement

SpringerLink
Log in

Biomarkers in systemic lupus erythematosus

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Despite the longstanding interest and large number of publications on biomarkers in lupus, there are no validated and widely accepted biomarkers of systemic lupus erythematosus to date. To achieve the ultimate goal, to have a biomarker as a surrogate endpoint in clinical studies, candidate biomarkers have to first be validated in a statistically rigorous way. However, to qualify as a surrogate endpoint, even validated biomarkers have to go through a process that demonstrates that they accurately reflect a clinically important outcome. These goals can only be achieved in large multicenter, properly conducted studies. We reviewed the difficulties involved in developing validated biomarkers for systemic lupus erythematosus and summarized the available data on the most promising biomarker candidates of disease susceptibility and disease activity. We also report on the current status of a multicenter initiative to concentrate efforts of biomarker development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89–95. Summary of National Institute of Health consensus meeting on biomarkers.

  2. Rolan P: The contribution of clinical pharmacology surrogates and models to drug development—a critical appraisal. Br J Clin Pharmacol 1997, 44:219- 225.

    Article  PubMed  CAS  Google Scholar 

  3. Lesko LJ, Atkinson AJ, Jr.: Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001, 41:347- 366.

    Article  PubMed  CAS  Google Scholar 

  4. Fleming TR, DeMets DL: Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996, 125:605- 613.

    PubMed  CAS  Google Scholar 

  5. Wagner JA: Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 2002, 18:41–46.

    PubMed  CAS  Google Scholar 

  6. Ward MM, Marx AS, Barry NN: Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000, 27:664- 670.

    PubMed  CAS  Google Scholar 

  7. Illei GG, Tackey E, Lapteva L, Lipsky PE: Biomarkers in systemic lupus erythematosus I. General overview of biomarkers and their applicability. Arthritis Rheum 2004, 50:1709- 1720. General overview of biomarkers, surrogate endpoints, and their validation and the applicability of this process to SLE. Detailed review of markers of disease susceptibility and organ involvement in lupus.

    Article  PubMed  CAS  Google Scholar 

  8. Illei GG, Lapteva L, Tackey E, Lipsky PE: Biomarkers in systemic lupus eythematosus II. Markers of disease activity. Arthritis Rheum 2004, 50:2048- 2065. Detailed summary of the published literature on biomarkers of disease activity in lupus.

    Article  PubMed  CAS  Google Scholar 

  9. Kelly JA, Moser KL, Harley JB: The genetics of systemic lupus erythematosus: putting the pieces together. Genes Immun 2002, 3(Suppl 1):S71- S85.

    Article  PubMed  CAS  Google Scholar 

  10. Karassa FB, Trikalinos TA, Ioannidis JP: Role of the fcgamma receptor IIa polymorphism in susceptibility to systemic lupus erythematosus and lupus nephritis: a meta-analysis. Arthritis Rheum 2002, 46:1563- 1571. This meta-analysis of 25 comparisons from 17 studies concludes that the Fcγ RIIa-R/H131 polymorphism represents a significant risk factor for SLE but has no clear effect on susceptibility for lupus nephritis.

    Article  PubMed  CAS  Google Scholar 

  11. Karassa FB, Trikalinos TA, Ioannidis JP: The Fc gamma RIIIAF158 allele is a risk factor for the development of lupus nephritis: a meta-analysis. Kidney Int 2003, 63:1475- 1482. This meta-analysis of 16 comparisons from 11 studies concludes that the Fcγ RIIIA-V/F158 polymorphism has a significant impact on the development of lupus nephritis.

    Article  PubMed  CAS  Google Scholar 

  12. Edberg JC, Langefeld CD, Wu J, et al.: Genetic linkage and association of Fcgamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus erythematosus. Arthritis Rheum 2002, 46:2132- 2140. This study demonstrated linkage and association of Fcγ RIIIA with SLE with family-based and case-control-based analysis in two large cohorts.

    Article  PubMed  CAS  Google Scholar 

  13. Kyogoku C, Dijstelbloem HM, Tsuchiya N, et al.: Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility. Arthritis Rheum 2002, 46:1242–1254.

    Article  PubMed  CAS  Google Scholar 

  14. Manger K, Repp R, Jansen M, et al.: Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms. Ann Rheum Dis 2002, 61:786- 792.

    Article  PubMed  CAS  Google Scholar 

  15. Garred P, Voss A, Madsen HO, Junker P: Association of mannose- binding lectin gene variation with disease severity and infections in a population-based cohort of systemic lupus erythematosus patients. Genes Immun 2001, 2:442- 450.

    Article  PubMed  CAS  Google Scholar 

  16. Prokunina L, Castillejo-Lopez C, Oberg F, et al.: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet 2002, 32:666- 669. One intronic single-nucleotide polymorphism in the PDCD1 gene showed a strong association with the development of SLE in Europeans and Mexicans but not in blacks in a cohort of 2510 individuals. The associated allele of this single nucleotide polymorphism alters a binding site for the runt-related transcription factor 1 that could lead to aberrant regulation of PDCD1, contributing to the disregulated self-tolerance and to the chronic lymphocyte hyperactivity characteristic of SLE.

    Article  PubMed  CAS  Google Scholar 

  17. Tjernstrom F, Hellmer G, Nived O, et al.: Synergetic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17,DQ2) in determining susceptibility to systemic lupus erythematosus. Lupus 1999, 8:103- 108.

    Article  PubMed  CAS  Google Scholar 

  18. Huang CM, Wu MC, Wu JY, Tsai FJ: Interleukin-1 receptor antagonist gene polymorphism in chinese patients with systemic lupus erythematosus. Clin Rheumatol 2002, 21:255- 257.

    Article  PubMed  Google Scholar 

  19. Tanaka Y, Nakashima H, Hisano C, et al.: Association of the interferon-gamma receptor variant (Val14Met) with systemic lupus erythematosus. Immunogenetics 1999, 49:266- 271.

    Article  PubMed  CAS  Google Scholar 

  20. Nakashima H, Inoue H, Akahoshi M, et al.: The combination of polymorphisms within interferon-gamma receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus. FEBS Lett 1999, 453:187–190.

    Article  PubMed  CAS  Google Scholar 

  21. Mehrian R, Quismorio FP, Jr., Strassmann G, et al.: Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 1998, 41:596- 602.

    Article  PubMed  CAS  Google Scholar 

  22. Arbuckle MR, McClain MT, Rubertone MV, et al.: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526- 1533. This study demonstrates that autoantibodies appear years before clinical symptoms and seem to follow an ordered temporal sequence.

    Article  PubMed  CAS  Google Scholar 

  23. Arbuckle MR, James JA, Kohlhase KF, et al.: Development of antidsDNA autoantibodies prior to clinical diagnosis of systemic lupus erythematosus. Scand J Immunol 2001, 54:211- 219.

    Article  PubMed  CAS  Google Scholar 

  24. Spronk PE, Bootsma H, Kallenberg CG: Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Guideline for treatment? Clin Rev Allergy Immunol 1998, 16:211- 218.

    CAS  Google Scholar 

  25. Bootsma H, Spronk P, Derksen R, et al.: Prevention of relapses in systemic lupus erythematosus. Lancet 1995, 345:1595- 1599.

    Article  PubMed  CAS  Google Scholar 

  26. Esdaile JM, Joseph L, Abrahamowicz M, Li Y, et al.: Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? J Rheumatol 1996, 23:1891- 1896.

    PubMed  CAS  Google Scholar 

  27. Esdaile JM, Abrahamowicz M, Joseph L, et al.: Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996, 39:370- 378.

    Article  PubMed  CAS  Google Scholar 

  28. Bootsma H, Spronk PE, ter Borg EJ, et al.: The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation. Ann Rheum Dis 1997, 56:661- 666.

    Article  PubMed  CAS  Google Scholar 

  29. Kallenberg CG, Bootsma H, Spronk PE, et al.: Laboratory tests as predictors of flares in systemic lupus erythematosus: comment on the article by Esdaile et al. Arthritis Rheum 1997, 40:393- 394.

    Article  PubMed  CAS  Google Scholar 

  30. Swaak AJ, Smeenk RJ: Following the disease course in systemic lupus erythematosus: are serologic variables of any use? J Rheumatol 1996, 23:1842- 1844.

    PubMed  CAS  Google Scholar 

  31. Zonana-Nacach A, Sanchez L, Camargo-Coronel A, et al.: Laboratory abnormalities and systemic lupus erythematosus flare: comment on the article by Esdaile et al. Arthritis Rheum 1997, 40:2092- 2093.

    Article  PubMed  CAS  Google Scholar 

  32. Ho A, Magder LS, Barr SG, Petri M: Decreases in anti-doublestranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001, 44:2342- 2349.

    Article  PubMed  CAS  Google Scholar 

  33. Ahearn J, Liu C-C, Navratil J, et al.: Erythrocyte C4D and CR1 as biomarkers for SLE [abstract]. Paper presented at the 7th International Congress of SLE and Related Conditions. New York, NY, May 9- 13, 2004.

  34. Baechler EC, Batliwalla FM, Karypis G, et al.: Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003, 100:2610- 2615. Compared with healthy controls, half of the lupus patients studied by RNA microarray showed dysregulated expression of genes in the IFN pathway. Furthermore, this IFN gene expression "signature" served as a marker for more severe disease involving the kidneys, hematopoetic cells, and/or the central nervous system.

    Article  PubMed  CAS  Google Scholar 

  35. Bennett L, Palucka AK, Arce E, et al.: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711- 723. Using oligonucleotide microarrays, active SLE could be distinguished by overexpression of granulopoiesis-related and IFN-induced genes. High dose glucocorticoids, shut down the interferon signature, further supporting the role of this cytokine in SLE. The expression of 10 genes correlated with disease activity. The most striking correlation was found with the formyl peptide receptor-like 1 protein that mediates chemotactic activities of defensins. Therefore, while the IFN signature confirms the central role of this cytokine in SLE, microarray analysis of blood cells reveals that immature granulocytes may be involved in SLE pathogenesis.

    Article  PubMed  CAS  Google Scholar 

  36. Kim T, Kanayama Y, Negoro N, et al.: Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987, 70:562- 569.

    PubMed  CAS  Google Scholar 

  37. Bengtsson AA, Sturfelt G, Truedsson L, et al.: Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000, 9:664–671.

    Article  PubMed  CAS  Google Scholar 

  38. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J: Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science 2001, 294:1540- 1543. Serum from SLE patients induced normal monocytes to differentiate into dendritic cells capable of capturing antigens from dying cells and present them to CD4-positive T cells. The capacity of SLE patients’ serum to induce dendritic cell differentiation correlated with disease activity and depended on the actions of IFN-α.

    Article  PubMed  CAS  Google Scholar 

  39. Laut J, Senitzer D, Petrucci R, et al.: Soluble interleukin-2 receptor levels in lupus nephritis. Clin Nephrol 1992, 38:179- 184.

    PubMed  CAS  Google Scholar 

  40. ter Borg EJ, Horst G, Limburg PC, Kallenberg CG: Changes in plasma levels of interleukin-2 receptor in relation to disease exacerbations and levels of anti-dsDNA and complement in systemic lupus erythematosus. Clin Exp Immunol 1990, 82:21- 26.

    Article  PubMed  Google Scholar 

  41. Swaak AJ, Hintzen RQ, Huysen V, et al.: Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course. Clin Rheumatol 1995, 14:293- 300.

    Article  PubMed  CAS  Google Scholar 

  42. Davas EM, Tsirogianni A, Kappou I, et al.: Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 1999, 18:17- 22.

    Article  PubMed  CAS  Google Scholar 

  43. Dejica D: Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy. Roum Arch Microbiol Immunol 2001, 60:183- 201.

    PubMed  CAS  Google Scholar 

  44. Spronk PE, ter Borg EJ, Huitema MG, et al.: Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 1994, 53:235- 239.

    Article  PubMed  CAS  Google Scholar 

  45. Gabay C, Cakir N, Moral F, et al.: Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997, 24:303- 308.

    PubMed  CAS  Google Scholar 

  46. Aderka D, Wysenbeek A, Engelmann H, et al.: Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993, 36:1111- 1120.

    Article  PubMed  CAS  Google Scholar 

  47. Aringer M, Feierl E, Steiner G, et al.: Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death. Lupus 2002, 11:102- 108.

    Article  PubMed  CAS  Google Scholar 

  48. Ho CY, Wong CK, Li EK, et al.: Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 2003, 42:117- 122.

    Article  CAS  Google Scholar 

  49. Horak P, Scudla V, Hermanovo Z, et al.: Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus. Clin Rheumatol 2001, 20:337- 344.

    Article  PubMed  CAS  Google Scholar 

  50. Ikeda Y, Fujimoto T, Ameno M, et al.: Relationship between lupus nephritis activity and the serum level of soluble VCAM- 1. Lupus 1998, 7:347- 354.

    Article  PubMed  CAS  Google Scholar 

  51. Janssen BA, Luqmani RA, Gordon C, et al.: Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. Br J Rheumatol 1994, 33:1112–1116.

    Article  PubMed  CAS  Google Scholar 

  52. Spronk PE, Bootsma H, Huitema MG, et al.: Levels of soluble VCAM-1, soluble ICAM-1, and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus (SLE); a long term prospective study. Clin Exp Immunol 1994, 97:439- 444.

    Article  PubMed  CAS  Google Scholar 

  53. Tesar V, Masek Z, Rychlik I, et al.: Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. Nephrol Dial Transplant 1998, 13:1662- 1667.

    Article  PubMed  CAS  Google Scholar 

  54. Kaplanski G, Cacoub P, Farnarier C, et al.: Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum 2000, 43:55- 64.

    Article  PubMed  CAS  Google Scholar 

  55. Boehme MW, Nawroth PP, Kling E, et al.: Serum thrombomodulin. A novel marker of disease activity in systemic lupus erythematosus. Arthritis Rheum 1994, 37:572- 577.

    Article  PubMed  CAS  Google Scholar 

  56. Frijns R, Fijnheer R, Schiel A, et al.: Persistent increase in plasma thrombomodulin in patients with a history of lupus nephritis: endothelial cell activation markers. J Rheumatol 2001, 28:514- 519.

    PubMed  CAS  Google Scholar 

  57. Kotajima L, Aotsuka S, Sato T: Clinical significance of serum thrombomodulin levels in patients with systemic rheumatic diseases. Clin Exp Rheumatol 1997, 15:59- 65.

    PubMed  CAS  Google Scholar 

  58. Jacobi AM, Odendahl M, Reiter K, et al.: Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:1332- 1342. The number and frequency of CD27high plasma cells significantly correlated with SLE disease activity indices and with the titer of antidsDNA antibodies. B cell abnormalities provided predictive values for nonactive and active disease of 78.0% and 78.9%, respectively.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Health and Human Services, National Institutes of Health, 10 Center Drive, Room 9S205, 20892, Bethesda, MD, USA

    Gabor G. Illei MD

Authors
  1. Gabor G. Illei MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter E. Lipsky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Illei, G.G., Lipsky, P.E. Biomarkers in systemic lupus erythematosus. Curr Rheumatol Rep 6, 382–390 (2004). https://doi.org/10.1007/s11926-004-0013-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-004-0013-4

Keywords

Search

Navigation